RxDoctor Payments Data

Kristin Grunbaum

Family · Jupiter, FLNPI 1114110228

Payments from drug & device makers

$4,128in general payments, 2019–2025

Across 175 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$518
  • AstraZeneca$512
  • Regeneron Healthcare Solutions, Inc.$450
  • Actelion Pharmaceuticals US, Inc.$312
  • Boehringer Ingelheim$262
  • Takeda Pharmaceuticals U.S.A., Inc.$251
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,03198%
  • Education$962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,128 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$25,742
Breo ElliptaFluticasone/Vilanterol24$14,949
Arnuity ElliptaFluticasone Furoate39$10,808
SymbicortBudesonide/Formoterol Fumarate11$5,784
Epinephrine21$5,033
Azelastine Hcl113$3,061
Montelukast Sodium152$1,617
Ipratropium Bromide28$721
Albuterol Sulfate HfaAlbuterol Sulfate23$510
Fluticasone Propionate17$381
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$144
Prednisone41$128
Azithromycin12$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$518$51,49988 claims
AstraZenecaSymbicort$512$5,78411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →